Breaking News
0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

DexCom Tumbles 12% After Earnings Miss, Analysts Say Plunge 'Greatly Exaggerated'

Stock Markets Jul 29, 2022 09:36
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
DXCM
+0.62%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Senad Karaahmetovic

Shares of DexCom Inc (NASDAQ:DXCM) plunged more than 12% in premarket Friday following weaker-than-expected Q2 results.

DexCom reported an adjusted EPS of 17c to miss on the expected 24c. Revenue was reported at $696.2 million, again lower than the estimate of $700.8 million. The weaker-than-expected results were driven by the soft performance of the US business, where revenues missed the average analyst estimate by c2.5%.

For the full year, DXCM sees revenues between $2.86 billion to $2.91 billion, an upgraded view compared to the prior outlook of $2.82 billion to $2.94 billion. Analysts were calling for a full-year revenue outlook of $2.92 billion.

A Stifel analyst believes the stock reaction is “greatly exaggerated” and “feels overdone.”

“We don’t believe there is any change in underlying market dynamics and expect 2H22/2023 growth to accelerate as G7 rolls-out, PCP traction increases, mix headwinds dissipate, and Basal coverage plays-out,” the analyst told clients.

An Oppenheimer analyst added that he is a buyer on weakness for the following reasons.

“1) US revenues missed estimates at 11% growth (OUS outperformed). Importantly, we estimate unit growth ~30% y/y with the delta to revenue growth DXCM's ongoing actions to shift current and new patients to the pharmacy channel. As pharmacy mix levels off, this delta should tighten. 2) A software change is being made to G7 based on FDA feedback, causing slight US launch delay (limited launch expected now 4Q). Visibility on getting the change into FDA sounds good as does the rest of the submission. Payer discussions continue, allowing for faster ramp upon launch. Buyers ahead of G7 and with T2/international building,” the analyst explained in a note.

DexCom Tumbles 12% After Earnings Miss, Analysts Say Plunge 'Greatly Exaggerated'
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email